
Please try another search
One stock that might be an intriguing choice for investors right now is HollyFrontier Corporation (NYSE:HFC) . This is because this security in the Oil and Gas- Refining and Marketing space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Oil and Gas- Refining and Marketing space as it currently has a Zacks Industry Rank of 51 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, HollyFrontier is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
HollyFrontier Corporation Price and Consensus
In fact, over the past month, current quarter estimates have risen from 76 cents per share to 91 cents per share, while current year estimates have risen from $2.07 per share to $2.36 per share. This has helped HFC to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here.
So, if you are looking for a decent pick in a strong industry, consider HollyFrontier. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
The markets have been sluggish this week as investors hope for a jolt later in the week when AI juggernaut NVIDIA Corporation (NASDAQ:NVDA) reports fourth quarter and year-end...
On Friday, a wave of selling pressure swept across the US equity markets, leaving a trail of losses. The S&P 500 closed down 1.7%, the DOW slid 1.69%, and the NASDAQ tumbled a...
Palantir remains highly valued with a 460x P/E ratio and a 42.5x P/B ratio, far above its peers. The stock's beta of 2.81 signals high volatility, meaning sharp moves in both...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.